Literature DB >> 7494339

The in vivo antiviral activity of interleukin-12 is mediated by gamma interferon.

L Ozmen1, M Aguet, G Trinchieri, G Garotta.   

Abstract

The injection of 20 ng of mouse interleukin-12 (IL-12) protects mice from a lethal infection with encephalomyocarditis virus. In vitro, an anti-gamma interferon (anti-IFN-gamma) monoclonal antibody but not an anti-IL-12 monoclonal antibody neutralizes the antiviral activity present in the supernatants of splenocytes stimulated with IL-12. Finally, IL-12 fails to protect 129 Sv/Ev IFN-gamma R0/0 mice against encephalomyocarditis virus infection. These results demonstrate that IL-12 exerts its antiviral activity through the induction of endogenous IFN-gamma.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7494339      PMCID： PMC189771     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  17 in total

1.  Regulation of human cytolytic lymphocyte responses by interleukin-12.

Authors:  M K Gately; A G Wolitzky; P M Quinn; R Chizzonite
Journal:  Cell Immunol       Date:  1992-08       Impact factor: 4.868

2.  IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones.

Authors:  P Parronchi; M De Carli; R Manetti; C Simonelli; S Sampognaro; M P Piccinni; D Macchia; E Maggi; G Del Prete; S Romagnani
Journal:  J Immunol       Date:  1992-11-01       Impact factor: 5.422

3.  Mechanisms of IFN-gamma induction by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2.

Authors:  S H Chan; M Kobayashi; D Santoli; B Perussia; G Trinchieri
Journal:  J Immunol       Date:  1992-01-01       Impact factor: 5.422

4.  IL-12 receptor. II. Distribution and regulation of receptor expression.

Authors:  B B Desai; P M Quinn; A G Wolitzky; P K Mongini; R Chizzonite; M K Gately
Journal:  J Immunol       Date:  1992-05-15       Impact factor: 5.422

5.  Human interferon alpha and gamma production by lymphocytes during the generation of influenza virus-specific cytotoxic T lymphocytes.

Authors:  Y K Yamada; A Meager; A Yamada; F A Ennis
Journal:  J Gen Virol       Date:  1986-11       Impact factor: 3.891

6.  A convenient and rapid cytopathic effect inhibition assay for interferon.

Authors:  P C Familletti; S Rubinstein; S Pestka
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

7.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.

Authors:  T R Mosmann; H Cherwinski; M W Bond; M A Giedlin; R L Coffman
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

8.  Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies.

Authors:  H M Cherwinski; J H Schumacher; K D Brown; T R Mosmann
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

9.  Response of resting human peripheral blood natural killer cells to interleukin 2.

Authors:  G Trinchieri; M Matsumoto-Kobayashi; S C Clark; J Seehra; L London; B Perussia
Journal:  J Exp Med       Date:  1984-10-01       Impact factor: 14.307

10.  Interleukin 12, interferon gamma, and tumor necrosis factor alpha are the key cytokines of the generalized Shwartzman reaction.

Authors:  L Ozmen; M Pericin; J Hakimi; R A Chizzonite; M Wysocka; G Trinchieri; M Gately; G Garotta
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307
View more
  14 in total

1.  Interferon beta transduction of peripheral blood lymphocytes from HIV-infected donors increases Th1-type cytokine production and improves the proliferative response to recall antigens.

Authors:  V Vieillard; I Cremer; E Lauret; W Rozenbaum; P Debré; B Autran; E De Maeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

2.  Interleukin-12 exhibits potent antiviral activity in experimental herpesvirus infections.

Authors:  J A Carr; J Rogerson; M J Mulqueen; N A Roberts; R F Booth
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Role of interleukin-12 in primary influenza virus infection.

Authors:  J M Monteiro; C Harvey; G Trinchieri
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

4.  Protection against lethal encephalomyocarditis virus infection in the absence of serum-neutralizing antibodies.

Authors:  Z C Neal; G A Splitter
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

5.  Interleukin-12 inhibits hepatitis B virus replication in transgenic mice.

Authors:  V J Cavanaugh; L G Guidotti; F V Chisari
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

6.  The immune response modifier imiquimod requires STAT-1 for induction of interferon, interferon-stimulated genes, and interleukin-6.

Authors:  R L Bottrel; Y L Yang; D E Levy; M Tomai; L F Reis
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

7.  Cerebral expression of interleukin-12 induces neurological disease via differential pathways and recruits antigen-specific T cells in virus-infected mice.

Authors:  Markus Hofer; Jürgen Hausmann; Peter Staeheli; Axel Pagenstecher
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

8.  Exogenous interleukin-12 protects against lethal infection with coxsackievirus B4.

Authors:  Daniel M Potvin; Dennis W Metzger; William T Lee; Doris N Collins; Arlene I Ramsingh
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  Innate immune response to encephalomyocarditis virus infection mediated by CD1d.

Authors:  Mark A Exley; Nancy J Bigley; Olivia Cheng; Angela Shaulov; Syed Muhammad Ali Tahir; Quincy L Carter; Jorge Garcia; Carren Wang; Kurt Patten; Harold F Stills; Frederick W Alt; Scott B Snapper; Steven P Balk
Journal:  Immunology       Date:  2003-12       Impact factor: 7.397

10.  Restoration of immune response by a cationic amphiphilic drug (AY 9944) in vitro: a new approach To chemotherapy against human immunodeficiency virus type 1.

Authors:  A Achour; J C Landureau; R Salerno-Goncalves; R Salerno-Concalves; J C Mazière; D Zagury
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.